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The first liver transplant performed in Hawaii was on May 17, 
1993 in a patient with end-stage liver disease caused by autoim-
mune hepatitis. Liver transplantation is a well-accepted treat-
ment for end-stage liver disease with a 1-year patient survival of 
80% to 85%. Early recognition of the appropriate candidate by 
primary care physicians and prompt referral to a liver transplant 
center are essential for optimal results. The indications, 
contraindications, organ procurement and allocation, complica-
tions, and results of liver transplantation are described. Finally, 
several controversial areas will be introduced, including liver 
transplant for alcoholic cirrhosis and hepatitis 8, and use of 
transjugular intrahepatic portosystemic shunts (TIPS). 
Case 1 
In 1989 a 60-year-old woman who has a very distant history 
of breast cancer had aCT scan that noted a cirrhotic liver. A 
follow-up CT scan in 1990 showed the cirrhosis was unchanged. 
She had received no blood transfusions and was asymptomatic. 
In 1990, she developed intermittent mental slowness and fa-
tigue. She was admitted in August 1992 for mental status 
changes, lethargy, and severe anemia. Her past medical history 
was significant only for a moderate amount of alcohol use, but 
none for more than a year. 
Her physical examination was notable for mental slowness 
and encephalopathy ,jaundice, scleral icterus, spider angiomata, 
and severe lower extremity edema. Her abdomen was distended 
with ascites and an umbilical hernia was present. 
Her laboratory data was: 
WBC: 5.2 x 109cells/mm3 Hgb- 10.3 gm/dl; Hct 28.8%; 
Platelets 98K; Protime: 18.2 sec; PTT 41 sec; Albumin 2.5 
gm/dl; Alk phos: 16.1 IU/1; Total Bilirubin: 7.6 mg/dl; 
AST: 91 IU/1; ALT: 37 IU/1; GGTP: 56 IU/1; Hep A,B,C; 
HIV: all negative; ANA titer 1:640; Antimitochondrial 
Ab<20; Alphafetoprotein 11.75. 
Studies performed included CT scan and ultrasound of the 
abdomen which confirmed cirrhosis, splenomegaly, and patent 
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vessels (portal vein, hepatic artery, hepatic veins, and vena 
cava). 
In summary, she had end-stage liver disease probably from 
autoimmune hepatitis with manifestations of encephalopathy, 
ascites, malnutrition, and severe fatigue. She was evaluated by 
the members of the Liver Transplant Selection Committee at St. 
Francis Medical Center who agreed she was a suitable candidate 
for transplant; she was placed on the waiting list in April1993. 
On May 17, 1993, a suitable donor of identical blood type 
became available. The donor was hemodynamically stable and 
had good liver function prior to procurement. The donor proce-
dure was done by the en-bloc technique, to include removal of 
the liver, pancreas and both kidneys. The donor organs were 
flushed with University of Wisconsin solution at 4°C. The 
pancreas was sent for use in Islet cell transplantation. The heart 
was procured by a separate heart team. 
The liver recipient procedure began shortly thereafter. The 
cirrhotic liver was removed and the new liver was placed in the 
standard fashion using veno-venous bypass to maintain hemo-
dynamic stability and prevent lower extremity swelling. The 
anastomoses included suprahepatic inferior vena cava (IVC), 
infrahepatic IVC, portal vein, hepatic artery, and bile duct. The 
entire procedure took 10 hours; cold ischemic time was 11 hours, 
and a total of 26 units of PRBCs were transfused. 
Postoperatively, she maintained excellent liver allograft func-
tion. Her coagulopathy resolved (protime 11.3 sec., fibrinogen 
458 mg/dl on the first post-operative day), she had no acidosis, 
and bile production was good. She also maintained good cardio-
vascular and renal function. She was given antilymphocyte 
globulin (ATGAM®)forinduction therapy. Maintenance immu-
nosuppression included prednisone, azathioprine, and 
cyclosporine. Her postoperative problems included febrile reac-
tions to ATGAM®, and a mild rejection on the twelfth postopera-
tive day which was treated with high-dose steroids. She was 
discharged on 21 days after the operation. She subsequently 
developed elevation of alkaline phosphatase and bilirubin, and 
cholangiograms suggested an extrinsic compression of the bile 
duct. She was found to have a mucocele of the cystic duct stump, 
which was drained intraoperatively. Her liver function tests 
returned to normal. 
She is currently 6 months postop with continued good livet 
allograft function and no further rejection episodes. Her immu-
nosuppression consists of prednisone and cyclosporine. She has 
gained weight (albumin 4.5 gm/dl), walks 3 miles each day, and 
performs household work. 
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Discussion 
Few medical discoveries have been as exciting as the devel-
opment ofliver transplantation. The first human liver transplant 
was performed in 1963 by Dr Thomas Starzl. His patient was a 
3-year-old boy with liver failure caused by biliary atresia; he 
died intraoperatively from uncontrollable hemorrhage. 1 Liver 
transplantation has come a long way since then-with numerous 
advancements in preservation solutions, surgical techniques, 
and immunosuppression. Liver transplantation now has become 
an accepted treatment for end-stage liver disease-more than 
2,900 liver transplants were performed in the United States in 
1991, with one-year survival rates as high as 80% to 90%. 
The above case illustrates the course of a fairly typical liver 
transplant. What follows is a discussion of liver transplantation 
to include indications/contraindications, the evaluation process, 
complications, and controversies. 
Who needs a liver transplant? 
There are 4 primary indications for liver transplant: 
1. Irreversible advanced chronic liver disease 
2. Neoplastic diseases 
3. Metabolic liver diseases 
4. Fulminant liver failure (usually from hepatitis B, 
autoimmune hepatitis or acetaminophen overdose) 
Not all patients with the above-listed diseases will need a liver 
transplant; proper selection of patients and timing of surgery are 
essential. The patient should have advanced liver disease with 
complications such that liver transplant will improve survival 
and quality oflife. General criteria for patient selection include: 
1. Intractable ascites, not responsive to diuretic therapy 
2. Uncontrolled variceal bleeding 
3. Poorly controlled encephalopathy 
4. Malnutrition 
5. Fatigue, interfering with normal daily activities 
6. Hepatorenal syndrome 
7. Recurrent spontaneous bacterial peritonitis 
Although the contraindications to liver transplant have become 
fewer with time, there are still 4 main contraindications: 
1. Active sepsis outside the hepatobiliary tree 
2. Malignancy outside the liver 
3. Advanced cardiopulmonary disease 
4.AIDS 
Age, prior portacaval shunt, chronic alcoholism, and portal 
vein thrombosis are not absolute contraindications; however, 
these patients must be selected carefully. Advanced chronic 
renal failure may be a contraindication in certain scenarios, but 
a combined liver-kidney transplant can be performed.2•3 
Who gets a liver transplant? 
Before becoming a liver transplant candidate, the patient 
must be formally evaluated by a team of health professionals to 
include a transplant surgeon, hepatologist, anesthesiologist, 
nurses, and social workers. Multiple laboratory tests are ob-
tained to assess the extent and etiology ofli ver failure. Serologic 
tests and tumor markers are also checked. An ultrasound exarni-
nation and CT scan of the liver are used to look for tumors and 
determine vessel patency. All patients undergo cardiac evalua-
tion with an EKG and echocardiogram and further testing is 
done for high risk patients. Psychosocial assessment is made to 
establish whether or not if the patient can adapt to the stresses of 
having a liver transplant, will be compliant with medications and 
postoperative care. Finally, the patient meets with a financial 
counselor. Members of the transplant selection committee will 
then meet to determine if a patient is an appropriate candidate. 
How does a candidate get a liver? 
When a patient is accepted as a candidate, he or she is placed 
on a waiting list. How a patient then gets a liver is largely 
regulated by a national organization called UNOS (United 
Network for Organ Sharing). It dictates the policies as to how 
donor organs are procured and distributed fairly .It oversees the 
actions of 261 transplant centers and 65 organ procurement 
organizations in order to distribute organs from nearly 4,300 
cadaveric donors to the more than 22,000 patients waiting for 
transplants. This data includes all types of organs-most are 
waiting for kidneys and about 1,300 are waiting for liver 
transplants. 
UNOS has divided the United States into 11 regions (Fig 1). 
When a donor liver becomes available, it is first used locally 
within the area of the organ procurement organization. If no 
suitable candidates are found, it is then offered within the region, 
and then nationally. The appropriate candidate for a donor liver 
is determined by the patient's size, blood type, time waiting on 
the list, and medical urgency status. Urgency status is the most 
important factor, and each patient is categorized into one of the 
4 statuses listed.3 
Status 1: Patient's level of functioning and overall health 
status are not yet affected by liver disease. 
Status 2: Patient requires ongoing/frequent medical care, 
hospitalizations may be necessary. 
Status 3: Patient is hospitalized and cannot be discharged. 
Status 4: Patient is in the intensive care unit with liver failure 
and life expectancy is less than 7 days. 
The entire system is continuously evaluated and improved by 
UNOS. Currently there is much debate as to whether major 
changes should be made in the allocation process. Some believe 
that giving priority to the sickest patients (Status 4) may not be 
practical because these patients already have many complica-
tions and are likely to have a higher mortality. 
What is the hospital course of a 
liver transplant patient? 
Performing the recipient operation of a liver transplant is 
probably the most complex and difficult of all abdominal 
surgical procedures. The procedure can take anywhere from 6 to 
18 hours and requires meticulous technique and a tremendous 
amount of patience (Fig 2). Intraoperative problems can include 
hypothermia, coagulopathy, hypocalcemia due to multiple trans-
fusions, and many hemodynamic changes caused by blood loss 
and reperfusion of the new liver. 
Immunosuppression is started at the time of surgery and will 
continue throughout the patient's life. Each transplant center has 
-
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Figure 1.-0rgans are distributed to local centers first, then within each of the 
11 regions as determined by the UNOS map. (Courtesy of Thomas L. Fabry, MD and 
Franklin M. Klion, MD from the book Guide to Uver Transplantation, lkagu-Shoin 
Medical Publishers, New York, New York; 1992) 
its own protocol and new drugs are continually introduced and 
tested. In general, maintenance immunosuppression is with a 
combination of steroids, azathioprine, and cyclosporine. Drugs 
such as antilymphocyte globulin and OKT3 (monoclonal anti-
body directed against CD3 molecule on T-cells) are used as 
induction therapy and to treat severe rejection episodes. FK506 
is a drug with properties similar to cyclosporine and can be used 
as maintenance therapy in place of cyclosporine for those 
patients with refractory rejection or intolerance to cyclosporine. 
FDA approval of this drug is expected in early 1994. 
What are the complications? 
Because liver transplants are such complex procedures and 
the patient is wrought with portal hypertension and coagulopathy, 
complications are common. About 20% to 40% of all patients 
will have a surgical complication requiring re-operation. Most 
common indications for operative intervention include bleed-
ing, infection, and bile duct problems.4..s 
Medical complications usually are related to immunologic 
problems, infections, or the side effects of medications. Rejec-
tion is common, and histologically proven rejection has been 
shown in one study to occur in 73% of patients.6 Primary graft 
nonfunction or dysfunction may be due to immunologic prob-
lems or problems during the organ procurement. Early infec-
tious complications usually are related to surgery. Later infec-
tious complications include viruses (cytomegalovirus, Epstein-
Barr virus) or opportunistic pathogens (pneumocystis, listeria). 
Finally patients may be at risk for lymphoproliferati ve disorders 
(due to immunosuppression) or recurrence of their original 
disease (especially hepatitis Band neoplasms). 
What are the results of liver transplantation? 
When patients are carefully selected and managed, the 1-year 
survival rate is 80% to 90% and the 5-year survival rate is 60% 
to 65%; however, these numbers will vary depending on the 
patient's original disease. The most favorable survival is ob-
tained when patients are transplanted for primary biliary cirrho-
Ftgure 2.-The completed liver transplant. Two methods of connecting the bile duct 
are depicted. (Courtesy of Thomas L. Fabry, MD and Franklin M. Klion, MD from the 
bookGuide to Uver Transplantation, lgaku-Shoin Med'JCal Publishers, New Vorl<, 
New York; 1992) 
sis and sclerosing cholangitis. Results are less favorable for 
hepatic neoplasms and hepatitis B. 
Should patients with alcoholic cirrhosis be 
transplanted? 
Alcoholic liver disease is the single most-common cause for 
liver problems in the United States, but transplantation for this 
is somewhat controversial. The argument against transplanta-
tion is that these patients are "morally blameworthy", have 
associated medical problems, and are prone to recurrent disease. 
A number of studies have refuted this theory: The University of 
Pittsburgh demonstrated that 85.9% of the survivors remain 
abstinent post-transplant, and 74% return to some type of 
productive work. Factors that were predictive of abstinence 
include 1) support of a significant other, 2) acceptance of alcohol 
as the cause for liver disease, 3) active involvement in an alcohol 
treatment program, and 4) existing job or education allowing 
subsequent employment,? In general, patients with alcoholic 
liver disease can do well following liver transplant. Survival 
rates are comparable to patients with liver failure for nonalco-
holic causes. Patient selection is absolutely essential, as only 
about 50% of all patients referred for transplant will be suitable 
candidates.8 
Should patients with viral hepatitis B be 
transplanted? 
An estimated 300,000 people will develop hepatitis B annu-
ally, with 15,000havingchronichepatitisBand300progressing 
to fulminant liver failure. 7 Many of these patients will need liver 
transplants, however, there is concern over the significant rate of 
recurrence of hepatitis. We have learned a few things about the 
patterns of recurrent disease following transplant. It occurs more 
commonly in those with chronic Hepatitis B with cirrhosis, and 
less frequently in those with fulminant disease. High recurrence 
is thought to be due to extrahepatic replication of the viruses in 
such areas as bone marrow, spleen, and pancreas. Immunosup-
pression post-transplant also has been shown to enhance viral 
-
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replication; specifically steroids were found to increase hepatitis 
B surface antigen production. A number of centers are using 
hepatitis B immune globulin as prophylaxis with improved 
results. The 5-year survival is generally lower (60%) when 
compared to transplantation for other disease (80%).9 Liver 
transplant for hepatitis B remains controversial; however, it is 
beneficial when performed in the proper setting. As we begin to 
understandimmunoprophylaxis and develop new antiviral agents, 
perhaps we can learn to control recurrent disease. 
What is TIPS? 
The latest addition to the armamentarium of treatments for 
liver failure is the trans jugular intrahepatic portosystemic shunt 
(TIPS). TIPS is a shunt that connects the portal venous system 
to the systemic circulation via the hepatic veins. It is essentially 
a portacaval shunt within the liver. These stents are placed by a 
skilled interventional radiologist with the assistance of high-
resolution fluoroscopy, digital subtraction angiography, and 
ultrasound. Indications include portal hypertension with com-
plications of bleeding varices, failed sclerotherapy, or ascites. 10 
TIPS serves as a good bridge to liver transplant by decreasing the 
intraoperative and perioperative blood loss. 11 
Conclusions 
The field of liver transplantation is exciting and dynamic. It 
is a well-accepted treatment for end-stage liver disease and 
when patients are carefully selected and managed, the 1-year 
survival rate is 80% to 90%. These are extraordinary results 
when it is considered this population of patients would not have 
survived their liver failure. With constant new developments in 
organ preservation, immunosuppression, immunoprophylaxis, 
and surgical techniques, results are likely only to improve. 
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Organ Donor 
Identification 
And Referral 
Compliments of 
SSANDOZ 
Age: Newborn to 70 Years 
Contraindications: fllV 
Sepsis 
Organ Donor Center of Hawaii 
24 Hours A Day 
599-7630 
Neighbor Islands call toll free 
(800) 695-6554 
SANDOZ PHARMACEUTICALS CORPORATION 
EAST HANOVER, NEW JERSEY 07936 
Classified Notices 
To place a classified notice: 
HMA members: Please send signed and typewrit-
ten ad to the HMA office. As a benefit of member-
ship, HMA members may place a complimentary 
one-time classified ad on a space-available basis. 
Nonmembers: Please call 536-7702 for a non-
member form. Rates are $1.50 a word with a mini-
mum of 20 words or $30. Not commissionable. 
Payment must accompany written order. 
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For Sale 
X-ray equipment-$3,500/best offer. Raytheon 
325R x-ray machine and Kodak X-Omat M6A-N 
processor kept in good condition. Call Central Medi-
cal Clinic, George Shojinaga 523-8611. 
Office for Lease 
Hawaii Kai Medical and Office Ctr.-808 SF avail-
able for sublease at negotiable rents. Vahe Kenadjian 
(R) 539-9600n35-0179 McCormack Properties. 
